Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expec ...

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

BioSkryb launches ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of MRD cells.

In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...

Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

A special blood drive was held Monday afternoon to honor a Cranston High School East teacher battling leukemia.